U.S. Markets closed

The Zacks Analyst Blog Highlights: Gilead, Acorda Therapeutics, Hyperion Therapeutics and Medivation

Zacks Equity Research

For Immediate Release
Chicago, IL – May 02, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead (GILD-Free Report), Acorda Therapeutics, Inc. (ACOR-Free Report), Hyperion Therapeutics, Inc. (HPTX-Free Report) and Medivation, Inc. (MDVN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday’s Analyst Blog:

3 Biotech Beats for This Earnings Season

The biotech industry had experienced an incredibly good run over the last couple of years and was off to a strong start this year as well. However, things changed from Mar 20, when a letter was issued to Gilead (GILD-Free Report) by the U.S. lawmakers questioning Gilead’s pricing of its recently approved hepatitis C virus (:HCV) treatment, Sovaldi. Gilead’s price was considered to be too expensive and came under heavy criticism.

The news not only brought down Gilead’s stock price, it also impacted other companies, on concerns that these companies too would find their new treatments coming under the same pricing scrutiny. The NYSE ARCA Biotech Index (^BTK) and NASDAQ Biotechnology Index (^NBI) have declined more than 10% each since then.

But things have been looking up for the biotech industry since last week with a few biotech companies reporting encouraging first quarter results. Gilead was a clear winner with Sovaldi bringing in sales of $2.3 billion in its first full quarter on the market, beating all expectations. The sales figure of the drug over-shadowed pricing concerns thanks to its strong efficacy profile.

Apart from strong earnings, acquisition deals and regulatory updates on pipeline candidates have also boosted the share prices of some biotech stocks in the last few days, including Hyperion (HPTX) benefitting from its announcement of an acquisition deal which will expand its orphan drug portfolio.

Although it may be a while before there is a sustained improvement in the biotech sector, it would be a good idea to zero in on a handful of biotech stocks that are poised to beat earnings estimates this quarter. An earnings beat should help these stocks gain investor confidence and show price improvement.

How to Pick?

Given the huge number of industry participants, pinpointing stocks that have the potential to beat estimates could appear to be a daunting task, but our proprietary methodology makes it fairly simple. One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank – Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) – and a positive Zacks Earnings ESP (Expected Surprise Prediction).

Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising in their next earnings announcement. It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate.

Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%.

Below are three biotech stocks we believe are best positioned to stand out this earnings season.

Acorda Therapeutics, Inc. (ACOR-Free Report) is a Zacks Rank #2 stock with an Earnings ESP of +225.00%. The Zacks Consensus Estimate for the first quarter stands at 4 cents. In the past 30 days, estimates (on an average) have inched up by 3 cents.

Acorda, an Ardsley, NY based commercial-stage biopharmaceutical company is focused on the development and commercialization of novel treatments that improve neurological function in people suffering from multiple sclerosis (MS), spinal cord injury (SCI) and other nervous system disorders.

Although Acorda did not deliver positive earnings surprises in three of the last four quarters, it looks poised to beat expectations this season. The company is expected to surpass expectations this quarter on the back of strong Ampyra sales. The drug is approved for the improvement of walking in multiple sclerosis patients.

Acorda is expected to report its first quarter earnings on May 6 before the opening bell.

California based Hyperion Therapeutics, Inc. (HPTX-Free Report) is another Zacks Rank #2 stock with an Earnings ESP of +200.00%. Hyperion focuses on the development and commercialization of novel therapeutics for the treatment of orphan diseases and hepatology disorders.

The Zacks Consensus Estimate for the first quarter stands at a loss of a penny. Hyperion has delivered positive earnings surprises in the three of the last four quarters with an average beat of 127.99% and is expected to beat expectations in the first quarter as well. The company is expected to beat on the back of sales from Ravicti and Buphenyl, both for the treatment of urea cycle disorders.

Hyperion is expected to report its first quarter results on May 6.

Another stock to look out this earnings season is Medivation, Inc. (MDVN-Free Report), carrying a Zacks Rank #3. The San Francisco-based company focuses on the development of novel small molecule drugs for the treatment of serious diseases for which there are limited treatment options. The company has a positive Earnings ESP of 1,033.33%.

Medivation delivered positive earnings surprises in each of the last four quarters with an average beat of 60.46%. The company swung back to earnings last quarter and is expected to keep the earnings streak alive this quarter as well. The company’s sole marketed product, Xtandi is expected to continue with its impressive performance in the first quarter.

Medivation is set to report its first quarter earnings after market close on May 8.

Bottom Line

Despite the recent sell-off in the biotech sector, fundamentals remain strong. Strong pipelines, innovative treatments and impressive results should help the sector rally. A sneak peek at the space for some outperformers, backed by a solid Zacks Rank and a positive Zacks Earnings ESP, could be a great idea for investors to gain this earnings season.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on GILD - FREE
Get the full Report on ACOR - FREE
Get the full Report on HPTX - FREE
Get the full Report on MDVN - FREE
Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on GILD

Read the analyst report on ACOR

Read the analyst report on HPTX

Read the analyst report on MDVN

Zacks Investment Research